Larry Altstiel, MD, PhD, chief medical officer of vTv Therapeutics, will speak today on the panel “Novel Approaches to Alzheimer’s Disease,” during the Neuro Advance Boston conference hosted by Harvard Medical School. Altstiel will detail the mechanisms of action of azeliragon, vTv Therapeutics’ investigative treatment for mild Alzheimer’s disease…
The Alzheimer’s Drug Discovery Foundation (ADDF) announced that a Georgetown University Medical Center researcher has been awarded a $2.1 million grant to conduct a Phase 2 clinical trial of low-dose nilotinib (Tasigna, a cancer therapy) in patients with Alzheimer’s disease. The grant was awarded as part of the ADDF’s…
The number of clinical trials evaluating possible treatments for Alzheimer’s disease is on the increase, according to a recent analysis conducted by ResearchersAgainstAlzheimer’s (RA2), a global network of Alzheimer’s researchers that is part of a non-profit organization promoting the study and treatment of this disease, called UsAgainstAlzheimer’s. The…
UsAgainstAlzheimer’s hosted the 2016 National Alzheimer’s Summit on Sept. 27–29, bringing together members of the U.S. Congress, scientific researchers, industry leaders, and people living with Alzheimer’s disease (AD) to press for greater investment in Alzheimer’s research, improvements in healthcare, and greater efforts to ease socioeconomic and cultural…
More research is essential to improve protocols for diagnosing Alzheimer’s disease in people with Down syndrome, but the ability to identify and care for those patients is enhanced significantly if clinicians are aware of specific circumstances and use a multi-disciplinary treatment strategy. Those findings are included in a study titled …
NeuroTherapia, a Cleveland Clinic spin-off biotech company, has received a $1.7 million funding commitment from the Alzheimer’s Drug Discovery Foundation to advance its lead drug candidate NTRX-07 — a selective cannabinoid type 2 (CB2) receptor agonist that can be orally administered — toward human clinical trials. This therapy targets…
One of the pathological hallmarks of Alzheimer’s disease is the accumulation of the protein, amyloid beta, in neurons, leading to the formation of plaques that impair brain function. Exactly how amyloid beta enters and becomes toxic to neuron, or nerve, cells, however, is a matter of debate — with a new…
The Association for Frontotemporal Degeneration (AFTD) is hosting its inaugural Hope Rising Benefit Sept. 29, to increase awareness of frontotemporal degeneration (FTD) and raise funds to support AFTD’s collaborative research, education for healthcare professionals and advocacy for affordable services. FTD is a disease process that damages the temporal…
Researchers report identifying the molecular mechanisms responsible for activating the neuroglobin gene, which scientists think may protect people from developing Alzheimer’s disease. Moreover, the researchers suggest that scientists should explore ways of activating the gene as potential treatments for Alzheimer’s disease. The study, titled “Identification of a novel…
September 21 was World Alzheimer’s Day, a fitting occasion to announce that a recent study from Finnish and Swedish researchers has confirmed that MedUni Vienna scientists were right: Multimodal everyday training does, indeed, have a beneficial effect upon cognitive abilities such as planning and implementing projects. That is true for…
Get regular updates to your inbox.